Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
BA.2.19ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
GY.2ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
XBF.10ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
GA.8ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
XAY.1.1.1ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
XBB.1.38ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
CT.1ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
BA.2.10.4ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
FF.1ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
DN.1.1.2ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
AY.56 (Delta)ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
AY.39.1.4ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
AY.91.1 (Delta)ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
AY.4.14 (Delta)ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
B.1.1.359ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
BN.1.5.1ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
BA.2.66ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
B.1.1.485ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
CP.3ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
B.1.177.73ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
AY.112.2 (Delta)ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
B.1.1.13ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
Q.8 (Alpha)ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
AY.122.1 (Delta)ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
B.3.1ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
AY.5.6 (Delta)ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
B.1.1.440ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
B.1.177.25ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
AY.23.2 (Delta)ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
AY.104 (Delta)ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
B.1.198ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
XAFORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
BC.2ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
P.1.17.1 (Gamma)ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
BA.2.3.16ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
B.1.177.41ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
B.1.1.375ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
BL.1.4ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
B.1.1.135NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-18845.2US
HN.4.1.1SYoung-STATACATGTCTCTGGGACCA20452176321782F-18860.4Singapore
BA.2.42SYoung-STATACATGTCTCTGGGACCA20452176321782F-18860.4Singapore
BA.2.31.1SYoung-STATACATGTCTCTGGGACCA20452176321782F-18860.4Singapore
FL.1.5SYoung-STATACATGTCTCTGGGACCA20452176321782F-18860.4Singapore
BA.2.82SYoung-STATACATGTCTCTGGGACCA20452176321782F-18860.4Singapore
BA.2.10.3SYoung-STATACATGTCTCTGGGACCA20452176321782F-18860.4Singapore
BA.2.55SYoung-STATACATGTCTCTGGGACCA20452176321782F-18860.4Singapore
BA.5.1.19ORF1abWon-ORF1abCATGTGTGGCGGTTCACTAT20501544115460F-18860.9South Korea
XCSNUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-18863US
XBB.1.16.25NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-18863US
AY.39.2 (Delta)SYoung-SATCCAGCCTCTTATTATGTTAGAC2437.52187621853R-18863.5Singapore
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used